BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 23567066)

  • 1. Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management.
    Sun M; Becker A; Tian Z; Roghmann F; Abdollah F; Larouche A; Karakiewicz PI; Trinh QD
    Eur Urol; 2014 Jan; 65(1):235-41. PubMed ID: 23567066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A non-cancer-related survival benefit is associated with partial nephrectomy.
    Sun M; Trinh QD; Bianchi M; Hansen J; Hanna N; Abdollah F; Shariat SF; Briganti A; Montorsi F; Perrotte P; Karakiewicz PI
    Eur Urol; 2012 Apr; 61(4):725-31. PubMed ID: 22172373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma.
    Bianchi M; Gandaglia G; Trinh QD; Hansen J; Becker A; Abdollah F; Tian Z; Lughezzani G; Roghmann F; Briganti A; Montorsi F; Karakiewicz PI; Sun M
    Urol Oncol; 2014 Jan; 32(1):46.e1-7. PubMed ID: 24054864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A population-based comparison of cancer-control rates between radical and partial nephrectomy for T1A renal cell carcinoma.
    Crépel M; Jeldres C; Sun M; Lughezzani G; Isbarn H; Alasker A; Capitanio U; Shariat SF; Arjane P; Widmer H; Graefen M; Montorsi F; Perrotte P; Karakiewicz PI
    Urology; 2010 Oct; 76(4):883-8. PubMed ID: 20932408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Partial Versus Radical Nephrectomy Effect on Other-cause Mortality, Cancer-specific Mortality, and 30-day Mortality in Patients Older Than 75 Years.
    Marchioni M; Preisser F; Bandini M; Nazzani S; Tian Z; Kapoor A; Cindolo L; Abdollah F; Tilki D; Briganti A; Montorsi F; Shariat SF; Schips L; Karakiewicz PI
    Eur Urol Focus; 2019 May; 5(3):467-473. PubMed ID: 29398456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of partial vs radical nephrectomy with regard to other-cause mortality in T1 renal cell carcinoma among patients aged ≥75 years with multiple comorbidities.
    Sun M; Bianchi M; Trinh QD; Hansen J; Abdollah F; Hanna N; Tian Z; Shariat SF; Montorsi F; Perrotte P; Karakiewicz PI
    BJU Int; 2013 Jan; 111(1):67-73. PubMed ID: 22612472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radical Versus Partial Nephrectomy for cT1 Renal Cell Carcinoma.
    Gershman B; Thompson RH; Boorjian SA; Lohse CM; Costello BA; Cheville JC; Leibovich BC
    Eur Urol; 2018 Dec; 74(6):825-832. PubMed ID: 30262341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer-specific and non-cancer-related mortality rates in European patients with T1a and T1b renal cell carcinoma.
    Zini L; Patard JJ; Capitanio U; Crepel M; de La Taille A; Tostain J; Ficarra V; Bernhard JC; Ferrière JM; Pfister C; Villers A; Montorsi F; Karakiewicz PI
    BJU Int; 2009 Apr; 103(7):894-8. PubMed ID: 19076131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overall survival and development of stage IV chronic kidney disease in patients undergoing partial and radical nephrectomy for benign renal tumors.
    Kaushik D; Kim SP; Childs MA; Lohse CM; Costello BA; Cheville JC; Boorjian SA; Leibovich BC; Thompson RH
    Eur Urol; 2013 Oct; 64(4):600-6. PubMed ID: 23280319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival after partial and radical nephrectomy for the treatment of stage T1bN0M0 renal cell carcinoma (RCC) in the USA: a propensity scoring approach.
    Badalato GM; Kates M; Wisnivesky JP; Choudhury AR; McKiernan JM
    BJU Int; 2012 May; 109(10):1457-62. PubMed ID: 21933334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall survival advantage with partial nephrectomy: a bias of observational data?
    Shuch B; Hanley J; Lai J; Vourganti S; Kim SP; Setodji CM; Dick AW; Chow WH; Saigal C;
    Cancer; 2013 Aug; 119(16):2981-9. PubMed ID: 23674264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a comparative study analyzing octogenarians with renal cell carcinoma in a competing risk analysis with patients in the seventh decade of life.
    May M; Cindolo L; Zigeuner R; De Cobelli O; Rocco B; De Nunzio C; Tubaro A; Coman I; Truss M; Dalpiaz O; Wolff I; Feciche B; Fenske F; Pichler M; Schips L; Figenshau RS; Madison K; Sánchez-Chapado M; Santiago Martin Mdel C; Salzano L; Lotrecchiano G; Waidelich R; Stief C; Sountoulides P; Brookman-May S; ;
    Urol Oncol; 2014 Nov; 32(8):1252-8. PubMed ID: 25129141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extent of lymphadenectomy does not improve the survival of patients with renal cell carcinoma and nodal metastases: biases associated with the handling of missing data.
    Sun M; Trinh QD; Bianchi M; Hansen J; Abdollah F; Tian Z; Shariat SF; Montorsi F; Perrotte P; Karakiewicz PI
    BJU Int; 2014 Jan; 113(1):36-42. PubMed ID: 23490031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the Unexpected Presence of Non-organ-confined Disease at Final Pathology Undermine Cancer Control in Patients with Clinical T1N0M0 Renal Cell Carcinoma Who Underwent Partial Nephrectomy?
    Capitanio U; Stewart GD; Klatte T; Akdogan B; Roscigno M; Marszalek M; Dell'Oglio P; Zaffuto E; Rodriguez Faba O; Salagierski M; Lingard J; Carini M; Ouzaid I; Mir MC; Montorsi F; Da Pozzo LF; Stief C; Minervini A; Brookman-May SD
    Eur Urol Focus; 2018 Dec; 4(6):972-977. PubMed ID: 28753867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiofrequency ablation versus partial nephrectomy in patients with solitary clinical T1a renal cell carcinoma: comparable oncologic outcomes at a minimum of 5 years of follow-up.
    Olweny EO; Park SK; Tan YK; Best SL; Trimmer C; Cadeddu JA
    Eur Urol; 2012 Jun; 61(6):1156-61. PubMed ID: 22257424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival after diagnosis of localized T1a kidney cancer: current population-based practice of surgery and nonsurgical management.
    Patel HD; Kates M; Pierorazio PM; Hyams ES; Gorin MA; Ball MW; Bhayani SB; Hui X; Thompson CB; Allaf ME
    Urology; 2014 Jan; 83(1):126-32. PubMed ID: 24246317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Percutaneous Ablation Versus Partial and Radical Nephrectomy for T1a Renal Cancer: A Population-Based Analysis.
    Talenfeld AD; Gennarelli RL; Elkin EB; Atoria CL; Durack JC; Huang WC; Kwan SW
    Ann Intern Med; 2018 Jul; 169(2):69-77. PubMed ID: 29946703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Routine adrenalectomy in patients with locally advanced renal cell cancer does not offer oncologic benefit and places a significant portion of patients at risk for an asynchronous metastasis in a solitary adrenal gland.
    Weight CJ; Kim SP; Lohse CM; Cheville JC; Thompson RH; Boorjian SA; Leibovich BC
    Eur Urol; 2011 Sep; 60(3):458-64. PubMed ID: 21514718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partial nephrectomy seems to confer a survival benefit relative to radical nephrectomy in metastatic renal cell carcinoma.
    Mazzone E; Nazzani S; Preisser F; Tian Z; Marchioni M; Bandini M; Capitanio U; Kapoor A; Tilki D; Montorsi F; Shariat SF; Saad F; Briganti A; I Karakiewicz P
    Cancer Epidemiol; 2018 Oct; 56():118-125. PubMed ID: 30173050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Partial nephrectomy is not associated with an overall survival advantage over radical nephrectomy in elderly patients with stage Ib-II renal masses: An analysis of the national cancer data base.
    Ristau BT; Handorf EA; Cahn DB; Kutikov A; Uzzo RG; Smaldone MC
    Cancer; 2018 Oct; 124(19):3839-3848. PubMed ID: 30207380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.